Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Monday

Key Points

• Krystal Biotech is expected to report Q3 2026 results before the market opens on November 2. Analysts anticipate earnings of $1.82 per share on revenue of $126.22 million.
• In the prior quarter, the company reported EPS of $1.79, exceeding consensus by $0.09, while revenue of $119.22 million fell short of estimates.
• Analysts maintain a generally bullish view, with the stock carrying an average “Buy” rating and a $377.20 price target. Shares recently opened at $311.50, compared with a 52-week range of $183.26 to $382.54.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of $1.82 per share and revenue of $126.22 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The business had revenue of $119.22 million during the quarter, compared to analysts' expectations of $120.93 million. On average, analysts expect Krystal Biotech to post $7.33 EPS for the current fiscal year and $8.78 EPS for the next fiscal year.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $311.50 on Monday. Krystal Biotech has a 1-year low of $183.26 and a 1-year high of $382.54. The company has a market cap of $9.22 billion, a PE ratio of 39.04 and a beta of 0.50. The company has a 50-day moving average of $339.36 and a two-hundred day moving average of $325.79.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a report on Wednesday, September 23rd. Jefferies Financial Group restated a "buy" rating and issued a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Bank of America upped their price objective on Krystal Biotech from $392.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, September 21st. Royal Bank Of Canada began coverage on Krystal Biotech in a research report on Friday, August 14th. They issued an "outperform" rating and a $400.00 price objective on the stock. Finally, Chardan Capital raised Krystal Biotech to a "strong-buy" rating in a research note on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $377.20.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.